Market closedNon-fractional
ANI Pharmaceuticals/ANIP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Ticker
ANIP
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Baudette, United States
Employees
642
Website
www.anipharmaceuticals.com
ANIP Metrics
BasicAdvanced
$1.2B
Market cap
38.35
P/E ratio
$1.62
EPS
0.81
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
0.81
Financial strength
Current ratio
3.949
Quick ratio
3
Long term debt to equity
60.75
Total debt to equity
60.928
Dividend payout ratio (TTM)
4.57%
Interest coverage (TTM)
1.52%
Management effectiveness
Return on assets (TTM)
3.91%
Return on equity (TTM)
8.71%
Valuation
Price to earnings (TTM)
38.354
Price to revenue (TTM)
2.239
Price to book
2.72
Price to tangible book (TTM)
5.41
Price to free cash flow (TTM)
12.399
Growth
Revenue change (TTM)
44.26%
Earnings per share change (TTM)
-193.69%
3-year revenue growth (CAGR)
34.38%
3-year earnings per share growth (CAGR)
7.85%
What the Analysts think about ANIP
Analyst Ratings
Majority rating from 5 analysts.
ANIP Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$137M
4.41%
Net income
$18M
1,554.55%
Profit margin
13.24%
1,495.18%
ANIP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.28
$1.27
$1.00
$1.21
-
Expected
$0.68
$0.84
$0.86
$1.00
$0.96
Surprise
88.93%
50.59%
16.96%
21.49%
-
ANIP News
AllArticlesVideos
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
GlobeNewsWire·2 weeks ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
GlobeNewsWire·4 weeks ago
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ANI Pharmaceuticals stock?
ANI Pharmaceuticals (ANIP) has a market cap of $1.2B as of July 26, 2024.
What is the P/E ratio for ANI Pharmaceuticals stock?
The price to earnings (P/E) ratio for ANI Pharmaceuticals (ANIP) stock is 38.35 as of July 26, 2024.
Does ANI Pharmaceuticals stock pay dividends?
No, ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next ANI Pharmaceuticals dividend payment date?
ANI Pharmaceuticals (ANIP) stock does not pay dividends to its shareholders.
What is the beta indicator for ANI Pharmaceuticals?
ANI Pharmaceuticals (ANIP) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ANI Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.